LAU-APL-04

LAU-APL-04 is an investigational drug candidate being developed by Vectans Pharma for the treatment of viral infections. It utilizes the proprietary Lauriad technology, which is a muco-adhesive buccal tablet formulation designed to adhere to the gum (gingiva) and provide sustained, controlled release of the active ingredient directly into the oral mucosa and systemic circulation. This delivery method aims to enhance local drug concentration at the site of infection while improving patient compliance compared to traditional oral or topical therapies. As of current pipeline reports, LAU-APL-04 is in early-stage clinical development (Phase 1/2), though the specific active pharmaceutical ingredient has not been publicly disclosed.